text: Trial Letdown Hits Possis Medical Shares of device maker Possis Medical (Nasdaq: POSS) are down 38 to \$19.20 after the company cut its fiscal 2005 earnings outlook after a trial involving its AngioJet blood clot treatment yielded disappointing results.